<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="utf8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Risteys – E4_DM2NASCOMP – detailed case counts by code</title>
		<style type="text/css">
body {
	font-family: sans-serif;
}
.bar-plot-full {
	width: 8rem;
	border-radius: 0.1rem;
	background-color: #f2f2f2;
}
.bar-plot-full div {
	background-color: #c7c7c7;
	height: 1rem;
	border-radius: 0.1rem;
}
		</style>
	</head>
	<body>

		<table>
			<tr>
				<th>Source</th>
				<th>Code</th>
				<th>Name</th>
				<th>Case count</th>
				<th>Share of cases (%)</th>
			</tr>

			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E11)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus</td>
					<td>31054</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 76.990207016239%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E11)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus</td>
					<td>28407</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 70.42766827817032%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD10(E118)</td>
					<td>Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>5335</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 13.22672616834015%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Avohilmo: Primary healthcare outpatient">PRIM_OUT</abbr></td>
					<td>PRIM_OUT_NOT_USED_ICD10(E118)</td>
					<td>Non-insulin-dependent diabetes mellitus - With unspecified complications. Not used in endpoint definition. POSSIBLY INACCURATE IN COMPLEX ENDPOINTS!</td>
					<td>5263</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 13.048221147886451%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E119)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>5004</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 12.406098921532168%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E119)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>4872</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 12.078839717367051%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Outpatient Hilmo">OUTPAT</abbr></td>
					<td>OUTPAT_ICD10(E118)</td>
					<td>Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>4435</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 10.995413412668897%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Outpatient Hilmo">OUTPAT</abbr></td>
					<td>OUTPAT_ICD10(E117)</td>
					<td>Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>3435</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 8.516177017478617%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD10(E117)</td>
					<td>Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>2973</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 7.370769802900706%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E11)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus</td>
					<td>2969</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 7.360852857319945%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E11)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus</td>
					<td>2764</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 6.852609396305938%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Avohilmo: Primary healthcare outpatient">PRIM_OUT</abbr></td>
					<td>PRIM_OUT_NOT_USED_ICD10(E117)</td>
					<td>Non-insulin-dependent diabetes mellitus - With multiple complications. Not used in endpoint definition. POSSIBLY INACCURATE IN COMPLEX ENDPOINTS!</td>
					<td>2478</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 6.143547787281517%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E11)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus</td>
					<td>1923</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 4.767571587950911%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(177)_ICD10(E11)</td>
					<td>Insulin glargine 300 U / ml, Non-insulin-dependent diabetes mellitus</td>
					<td>983</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 2.4370893764720467%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E11)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus</td>
					<td>891</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 2.2089996281145408%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Outpatient Hilmo">OUTPAT</abbr></td>
					<td>OUTPAT_ICD10(E116)</td>
					<td>Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>874</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 2.166852609396306%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Avohilmo: Primary healthcare outpatient">PRIM_OUT</abbr></td>
					<td>PRIM_OUT_NOT_USED_ICD10(E116)</td>
					<td>Non-insulin-dependent diabetes mellitus - With other specified complications. Not used in endpoint definition. POSSIBLY INACCURATE IN COMPLEX ENDPOINTS!</td>
					<td>785</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.9462005702243708%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD10(E116)</td>
					<td>Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>704</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.745382422213958%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E119)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>636</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.5767943473410189%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Cause of death">DEATH</abbr></td>
					<td>DEATH_ICD10(E117)</td>
					<td>Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>623</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.5445642742035453%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E118)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>597</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.480104127928598%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E118)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>588</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.4577910003718855%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E119)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>501</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.242097433990331%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Cause of death">DEATH</abbr></td>
					<td>DEATH_ICD10(E118)</td>
					<td>Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>425</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.0536754679558697%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(358)_ICD10(E11)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus</td>
					<td>377</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.934672120986736%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(310)_ICD10(E11)</td>
					<td>Orlistat, sibutramine and other major and expensive medicines used to treat obesity, Non-insulin-dependent diabetes mellitus</td>
					<td>362</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.8974835750588819%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E119)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>253</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.6272468079831413%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD9(2507A)</td>
					<td>Diabetes mellitus, Diabetes with peripheral circulatory disorders</td>
					<td>224</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.5553489525226231%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E119)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>189</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.4685756786909632%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E117)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>104</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.25784058509978924%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(358)_ICD10(E119)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>89</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.22065203917193504%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E117)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>87</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.21569356638155446%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E112)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>74</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.18346349324408082%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E118)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>74</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.18346349324408082%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E112)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>72</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.17850502045370026%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E118)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>70</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.1735465476633197%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E117)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>68</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.16858807487293911%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD9(E11)</td>
					<td>Diabetes, insulin-treated, Name not found</td>
					<td>62</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.15371265650179744%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E114)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With neurological complications</td>
					<td>59</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.14627494731622662%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E112)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>58</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.14379571092103632%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E114)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With neurological complications</td>
					<td>57</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.14131647452584603%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E112)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>57</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.14131647452584603%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E116)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>56</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.13883723813065577%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(177)_ICD10(E119)</td>
					<td>Insulin glargine 300 U / ml, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>56</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.13883723813065577%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E117)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>54</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.1338787653402752%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E116)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>53</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.13139952894508491%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Cause of death">DEATH</abbr></td>
					<td>DEATH_ICD10(E116)</td>
					<td>Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>47</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.11652411057394323%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Inpatient Hilmo">INPAT</abbr></td>
					<td>INPAT_ICD9(2508A)</td>
					<td>Diabetes mellitus, Diabetes with other specified manifestations</td>
					<td>41</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.10164869220280154%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E113)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>38</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.09421098301723069%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E113)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>38</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.09421098301723069%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E117)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>36</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.08925251022685013%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E117)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>36</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.08925251022685013%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E113)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>33</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.08181480104127929%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E110)</td>
					<td>Diabetes, insulin-treated, Name not found</td>
					<td>31</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.07685632825089872%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E113)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>31</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.07685632825089872%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E112)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>27</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.0669393826701376%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E110)</td>
					<td>Diabetes, non-insulin-treated, Name not found</td>
					<td>27</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.0669393826701376%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Cause of death">DEATH</abbr></td>
					<td>DEATH_ICD9(2507A)</td>
					<td>Diabetes mellitus, Diabetes with peripheral circulatory disorders</td>
					<td>26</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.06446014627494731%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E114)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With neurological complications</td>
					<td>26</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.06446014627494731%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E112)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>24</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.05950167348456676%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E114)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With neurological complications</td>
					<td>24</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.05950167348456676%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E118)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>22</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.05454320069418619%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E111)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With ketoacidosis</td>
					<td>20</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.04958472790380564%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E118)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>20</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.04958472790380564%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E111)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With ketoacidosis</td>
					<td>17</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.04214701871823478%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E113)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>15</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.03718854592785422%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(358)_ICD10(E112)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With renal complications</td>
					<td>15</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.03718854592785422%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E116)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>14</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.03470930953266394%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(358)_ICD10(E117)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With multiple complications</td>
					<td>13</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.032230073137473655%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E114)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - With neurological complications</td>
					<td>12</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.02975083674228338%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD10(E115)</td>
					<td>Diabetes, insulin-treated, Non-insulin-dependent diabetes mellitus - With peripheral circulatory complications</td>
					<td>11</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.027271600347093094%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E113)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>11</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.027271600347093094%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(346)_ICD10(E116)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>10</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.02479236395190282%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(162)_ICD10(E114)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With neurological complications</td>
					<td>9</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.022313127556712532%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(215)_ICD10(E115)</td>
					<td>Diabetes, non-insulin-treated, Non-insulin-dependent diabetes mellitus - With peripheral circulatory complications</td>
					<td>9</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.022313127556712532%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(310)_ICD10(E119)</td>
					<td>Orlistat, sibutramine and other major and expensive medicines used to treat obesity, Non-insulin-dependent diabetes mellitus - Without complications</td>
					<td>9</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.022313127556712532%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(177)_ICD10(E118)</td>
					<td>Insulin glargine 300 U / ml, Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>8</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.019833891161522253%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(358)_ICD10(E113)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With ophthalmic complications</td>
					<td>7</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.01735465476633197%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(160)_ICD10(E116)</td>
					<td>exenatide, Non-insulin-dependent diabetes mellitus - With other specified complications</td>
					<td>6</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.01487541837114169%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="Cause of death">DEATH</abbr></td>
					<td>DEATH_ICD9(2508A)</td>
					<td>Diabetes mellitus, Diabetes with other specified manifestations</td>
					<td>5</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.01239618197595141%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(103)_ICD8(E11)</td>
					<td>Diabetes, insulin-treated, Name not found</td>
					<td>5</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.01239618197595141%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(285)_ICD10(E115)</td>
					<td>Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults), Non-insulin-dependent diabetes mellitus - With peripheral circulatory complications</td>
					<td>5</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.01239618197595141%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(358)_ICD10(E118)</td>
					<td>liraglutide, Non-insulin-dependent diabetes mellitus - With unspecified complications</td>
					<td>5</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.01239618197595141%"></div>
						</div>
						
					</td>
				</tr>
			

		</table>

	</body>
</html>
